The addition of the epidermal growth factor receptor (EGFR) inhibitor cetuximab (CTX) to chemotherapy (CT) did not offer an overall survival (OS) benefit in patients with resectable colorectal liver metastasis (CRLM) compared with CT alone, updated results of the New EPOC trial has shown.
The combination therapy of nivolumab (NIVO) and cabozantinib (CABO) with or without ipilimumab (IPI) demonstrates activity in advanced hepatocellular carcinoma (aHCC), according to the CheckMate 040* study presented at ASCO GI 2020.
The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.
A 12-month course of biweekly infusion of belapectin is safe and induces significant reductions in hepatic venous pressure gradient (HVPG) or fibrosis, in addition to preventing the development of varices, in the subgroup of nonalcoholic steatohepatitis (NASH) patients with cirrhosis but without oesophageal varices, as shown in the results of a phase IIb study.
Patients with nonalcoholic fatty liver disease (NAFLD) tend to consume more energy, macronutrients, added sugar and fructose than the controls, as shown in a Singapore study. Waist circumference and energy consumption, but not fructose intake, significantly correlate with NAFLD.
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Dr Dariusz P. Olszyna, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the importance of early detection to prevent the spread and complications related to sexually-transmitted infections (STIs).
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).